



Press Release

November 25, 2004

Uppsala, Sweden

Gyros AB announces license and development agreement with Fujirebio Inc, Japan

Gyros AB announced today that it has signed a non-exclusive license and development agreement with Fujirebio Inc. for diagnostic applications using Gyros' proprietary Compact Disc technology.

Under the terms of the agreement, Fujirebio will investigate combining Gyros' Compact Disc technology with its own chemiluminescence immunoassay platform, in order to develop a new system for diagnostic applications.

Jan Würtz, CEO & President of Gyros AB said; "Gyros has now reached an important milestone in its effort of commercialize its unique microfluidics technology for clinical diagnostic applications. Miniaturization and integration of immunoassays using Gyros' Compact Disk format could give significant productivity gains compared to traditional ways of working."

About Gyros AB

Gyros AB was founded in 2000 when it was spun off from Amersham Pharmacia Biotech. Gyros miniaturizes and integrates many steps of laboratory applications, enabling users to generate more information from less sample and to improve lab performance. Gyros aims to realize the full potential of its technology platform in the field of Life Science. Gyros has 70 employees working at its headquarters in Uppsala Science Park, Sweden and in sales offices in the USA and Europe.

For further information about Gyros AB, visit www.gyros.com

About Fujirebio Inc.

Fujirebio Inc., founded in 1950, is recognized as a leading in vitro diagnostic company and has successfully introduced fully automated and random access immuno-chemiluminescent systems, such as LUMIPULSE-forte. More than 900 LUMIPULSE-forte systems are currently working in Japan. Other products, including blood screening products such as SERODIA and GENEDIA agglutination assay kits, and immunochromatographic products, ESPLINE test kits, are also broadly used. With its strong R&D capabilities, Fujirebio is aiming to be a global life science company. Fujirebio is headquartered in Tokyo, Japan and has approximately 700 employees.

For further information about Fujirebio Inc., visit www.fujirebio.co.jp

Gyros

Mats Fischier, Chairman,
Gyros AB
Tel: +46 (0)431 360 710
Mobile: +46 (0)70 595 1821
Email: mats.fischier@gyros.com

Jan Würtz, President and CEO,
Gyros AB
Tel: +46 (0)18 566 400
Mobile: +46 (0)70 592 5670
Email: jan.wurtz@gyros.com

Fujirebio Inc.

Akira Uchida, Head,
IR & Public Relations Team,
Fujirebio Inc.
Tel: +81 3 5695 9268
Email: ar-uchida@fujirebio.co.jp

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

Gyros, Gyrolab and the Gyros logo are registered trademarks of Gyros AB.